Speak directly to the analyst to clarify any post sales queries you may have.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a highly precise and efficient genome-editing tool derived from a bacterial defense mechanism, which allows for targeted manipulation of the DNA sequence within an organism's genome. This innovative biotechnology tool enables precise genome editing through RNA-guided Cas9 nucleases, facilitating targeted genetic modifications across healthcare, agriculture, and bioenergy industries. Increased funding for research activities, advancements in gene therapy, the growing prevalence of genetic disorders, and the need for more efficient crop production methods increase the use of CRISPR technology. However, ethical concerns surrounding gene editing, especially in human germline cells, and regulatory hurdles in different regions may impede the adoption or commercialization of CRISPR products. Nevertheless, creating new genetically modified crops (GMO) with enhanced nutritional value or resistance to pests and diseases and advancing drug discovery by screening large libraries of compounds against specific targets using CRISPR systems creates lucrative opportunities for the CRISPR technology market.
Regional Insights
In America, the CRISPR technology market represents significant growth due to extensive research and development activities, substantial investments by both public and private sectors, and advances in bioinformatics. In addition, robust and steadily growing sectors such as agriculture, biotechnology, drug discovery, and therapeutics increased demand for CRISPR technology. The APAC region boasts increasing biopharmaceutical industries investing heavily in gene-editing technologies for agricultural advancements and disease treatment applications. Additionally, factors such as government support for genomics research and strategic collaborations with international organizations have accelerated market growth in this region. Europe has experienced considerable growth due to its well-established pharmaceutical infrastructure and funding from various organizations for genome editing research projects. Moreover, the Middle-East and Africa sub-segments focus on therapeutic applications of CRISPR for diseases such as sickle cell anemia and beta-thalassemia.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the CRISPR Technology Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the CRISPR Technology Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the CRISPR Technology Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Applied StemCell, Inc., Beam Therapeutics Inc., Caribou Biosciences, Inc., Cellectis S.A., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., ERS Genomics Limited, Function Oncology, GeneCopoeia, Inc., GenScript Biotech Corporation, Horizon Discovery Group Ltd. by Revvity, Inc., Inscripta, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Mammoth Biosciences, Inc., Merck KGaA, New England Biolabs, Inc., OriGene Technologies, Inc., Prime Medicine, Inc., Scribe Therapeutics, Sherlock Biosciences, Inc., Synthego Corporation, Takara Holdings Inc., Thermo Fisher Scientific Inc., ToolGen, Inc., TriLink BioTechnologies by Maravai Intermediate Holdings, LLC, Twist Bioscience Corporation, and Verve Therapeutics, Inc.Market Segmentation & Coverage
This research report categorizes the CRISPR Technology Market to forecast the revenues and analyze trends in each of the following sub-markets:- Offering
- Product
- Enzymes
- Guide RNA
- Kits & Reagents
- Services
- Cell Line Engineering
- gRNA Design & Vector Construction
- Screening Services
- Product
- Application
- Agricultural
- Biomedical
- Industrial
- End User
- Academics & Government Research Institutes
- Biotechnology Companies
- Agricultural Companies
- Pharmaceutical Companies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Georgia
- Illinois
- Kentucky
- Michigan
- Mississippi
- New Jersey
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as
- What is the market size and forecast of the CRISPR Technology Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the CRISPR Technology Market?
- What are the technology trends and regulatory frameworks in the CRISPR Technology Market?
- What is the market share of the leading vendors in the CRISPR Technology Market?
- Which modes and strategic moves are suitable for entering the CRISPR Technology Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
Companies Mentioned
- Agilent Technologies, Inc.
- Applied StemCell, Inc.
- Beam Therapeutics Inc.
- Caribou Biosciences, Inc.
- Cellectis S.A.
- CRISPR Therapeutics AG
- Danaher Corporation
- Editas Medicine, Inc.
- ERS Genomics Limited
- Function Oncology
- GeneCopoeia, Inc.
- GenScript Biotech Corporation
- Horizon Discovery Group Ltd. by Revvity, Inc.
- Inscripta, Inc.
- Intellia Therapeutics, Inc.
- Lonza Group Ltd.
- Mammoth Biosciences, Inc.
- Merck KGaA
- New England Biolabs, Inc.
- OriGene Technologies, Inc.
- Prime Medicine, Inc.
- Scribe Therapeutics
- Sherlock Biosciences, Inc.
- Synthego Corporation
- Takara Holdings Inc.
- Thermo Fisher Scientific Inc.
- ToolGen, Inc.
- TriLink BioTechnologies by Maravai Intermediate Holdings, LLC
- Twist Bioscience Corporation
- Verve Therapeutics, Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 195 |
Published | March 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 3.25 Billion |
Forecasted Market Value ( USD | $ 9.49 Billion |
Compound Annual Growth Rate | 16.4% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |